Bibliografisk note

Funding Information:
Mats C. Højbjerg Lassen was funded by a research grant from Herlev and Gentofte Hospital and the Danish Heart Foundation (grant no. 21-R149-A10082-22194). Tor Biering-Sørensen was funded by Herlev and Gentofte Hospital, Fondsbørsvekselerer Henry Hansen og Hustrus Hovedlegat, the Lundbeck Foundation, and the Novo Nordisk Foundation.Conflicts of Interest: T.B.S. is a Steering Committee member of the Amgen-financed GALACTIC-HF trial; is on the Steering Committee of the Boston Scientific–financed LUX-Dx TRENDS trial; is on the Advisory Boards of Sanofi Pasteur and Amgen; received speaker honoraria from Novartis and from Sanofi Pasteur; and received research grants from GE Healthcare and Sanofi Pasteur. The remaining authors have no conflicts to disclose.

Funding Information:
Mats C. Højbjerg Lassen was funded by a research grant from Herlev and Gentofte Hospital and the Danish Heart Foundation (grant no. 21-R149-A10082-22194 ). Tor Biering-Sørensen was funded by Herlev and Gentofte Hospital , Fondsbørsvekselerer Henry Hansen og Hustrus Hovedlegat , the Lundbeck Foundation , and the Novo Nordisk Foundation .